Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab + ZL-1310 +/- Durvalumab in Small Cell Lung Cancer
NCT07531095Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Apr 2026
- Primary completion
- May 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), T-cell Engagers
- Countries
- 9
01
Overview
Phase 1, open-label trial of zocilurtatug pelitecan and tarlatamab in small cell lung cancer (SCLC) (3 arms), sponsored by Amgen. Primary endpoints: Treatment-emergent Adverse Events up to 3.5 years and Dose-limiting Toxicities. Started Apr 2026; status: recruiting.
02
Drugs
zocilurtatug pelitecantarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07531095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07531095.